Core Insights - China Medical Group (08225) successfully held the "AI-RWS Real World Research Summit" in Shanghai, launching over ten AI-driven real-world research projects targeting high-prevalence mental disorders among Chinese youth and behavioral and psychological symptoms in dementia, marking a significant step in the company's strategic layout in the "AI + Clinical Research" sector, further consolidating its industry-leading position [1] Academic and Research System - The forum gathered 40 authoritative experts in pediatric, adolescent psychiatry, and geriatric cognitive disorders, learning from institutions like Stanford University and Mayo Clinic, and referencing the latest evidence-based guidelines from JAMA Psychiatry 2024 to construct a comprehensive research system integrating AI smart classification, personalized treatment path optimization, dynamic efficacy and safety prediction, and early warning of relapse risk [2] Core Sector Layout and Key Products - Youth Mental Disorders Sector: The company initiated an AI-RWS study covering over 30 institutions in 15 cities nationwide, targeting over 10,000 patients, focusing on the treatment of over 30 million affected youth in China. The study includes the exploration of combined or sequential treatments involving new drugs such as Xixin A, Xixin E, Xixin L, Xixin A, Xixin S, and Xixin L, aiming to optimize research protocols and predict disease progression [3] - Dementia and BPSD Sector: The "Star Plan" aims to build the largest and longest-followed BPSD real-world database in China, planning to include 100,000 patients over five years, focusing on non-drug interventions and combination therapies, providing critical data for innovative drug registration and post-marketing safety evaluations [3] - The company has obtained exclusive clinical research rights for key products like Xienka micro-patch and Xienmei flash tablets, which are recommended for treating mild to moderate dementia [4] Commercialization Path and Future Outlook - The company employs a diversified funding model involving collaboration with research hospitals, pharmaceutical companies, government projects, and insurance co-payments, with individual projects valued from millions to billions [5] - Leveraging platforms like Hainan Boao and Hengqin, the company can reduce the duration of Phase IV clinical studies by over 30%, aligning research outcomes with national health strategies, thus benefiting from policy advantages [5] - The company aims to focus on AI-RWS research and the development of intelligent physician agents, with core layouts in the Xixin mental health brand, Xien neurological brand, and Baimin allergic reaction brand, aspiring to become a global leader in the field and accelerate the transition to AI-driven clinical research services for enhanced shareholder value [5]
中国医疗集团重磅启动多项AI-RWS研究 领跑“AI+临床研究”新赛道